Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) |
Gene disruption
|
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 35264080 |
MR4 number |
|
top of page |
Parent parasite used to introduce the genetic modification |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone |
Not applicable
|
Other information parent line | |
top of page |
The mutant parasite was generated by |
Name PI/Researcher | Kumari V, Pandey KC |
Name Group/Department | ICMR-National Institute of Malaria Research |
Name Institute | ICMR-National Institute of Malaria Research |
City | New Delhi |
Country | India |
top of page |
Name of the mutant parasite |
RMgm number | RMgm-5182 |
Principal name | PbΔPbMCA-2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page |
Phenotype |
Asexual blood stage | In the manuscript evidence is presented for: reduced growth of asexual blood stages, reduced gametocyte production (2.7 fold); reduced exflagellation, reduced ookinete formation, ookinete growth arrestment during early development, reduced oocyst production, reduced sporozoite production |
Gametocyte/Gamete | In the manuscript evidence is presented for: reduced growth of asexual blood stages, reduced gametocyte production (2.7 fold); reduced exflagellation, reduced ookinete formation, ookinete growth arrestment during early development, reduced oocyst production, reduced sporozoite production |
Fertilization and ookinete | In the manuscript evidence is presented for: reduced growth of asexual blood stages, reduced gametocyte production (2.7 fold); reduced exflagellation, reduced ookinete formation, ookinete growth arrestment during early development, reduced oocyst production, reduced sporozoite production |
Oocyst | In the manuscript evidence is presented for: reduced growth of asexual blood stages, reduced gametocyte production (2.7 fold); reduced exflagellation, reduced ookinete formation, ookinete growth arrestment during early development, reduced oocyst production, reduced sporozoite production |
Sporozoite | In the manuscript evidence is presented for: reduced growth of asexual blood stages, reduced gametocyte production (2.7 fold); reduced exflagellation, reduced ookinete formation, ookinete growth arrestment during early development, reduced oocyst production, reduced sporozoite production |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation
The mutant lacks expression of Metacaspase-2 (MCA-2) and expresses GFP
Protein (function)
Metacaspases are cysteine-dependent proteases sharing the conserved His-Cys catalytic dyad of caspases (13). These proteases are members of the C14 family, clan CD, with a difference in substrate specificity compared to caspases (14). In addition, metacaspases have a highly acidic S1 pocket leading to arginine and lysine substrate specificity at the P1 position, compared to the aspartic acid specificity reported for caspases.
Three metacaspases have been identified in Plasmodium. MCA1: PF3D7_1354800, PBANKA_1131400; MCA2 :PF3D7_1354800, PBANKA_1131400; MCA3: PF3D7_1416200, PBANKA_1026500
Phenotype
In the manuscript evidence is presented for: reduced growth of asexual blood stages, reduced gametocyte production (2.7 fold); reduced exflagellation, reduced ookinete formation, ookinete growth arrestment during early development, reduced oocyst production, reduced sporozoite production
Additional information
Other mutants |